Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial

Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial

Background Trimethylamine N‐oxide (TMAO) may have prothrombotic properties. We examined the association of TMAO quartiles with major adverse cardiovascular events (MACE) and the effect of TMAO on the efficacy of ticagrelor. Methods and Results PEGASUS‐TIMI 54 (Prevention of Cardiovascular Events in...

Full description

Bibliographic Details
Main Authors: Baris Gencer, Xinmin S. Li, Yared Gurmu, Marc P. Bonaca, David A. Morrow, Marc Cohen, Deepak L. Bhatt, P. Gabriel Steg, Robert F. Storey, Per Johanson, Zeneng Wang, Stanley L. Hazen, Marc S. Sabatine
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
antiplatelet therapy
cardiovascular death
gut microbiota
myocardial infarction
stroke
ticagrelor
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.119.015331

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.119.015331

Similar Items